Fenofibrate discontinuation and the association with clinical outcomes in primary biliary cholangitis patients receiving combination therapy
{{output}}
Introduction: Fenofibrate serves as a second-line therapy in combination with ursodeoxycholic acid (UDCA) for patients with primary biliary cholangitis (PBC). However, a substantial proportion of patients discontinue treatment in... ...
